Cargando…
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
BACKGROUND: This study investigates whether a histone deacetylase subtype 6 (HDAC6) inhibitor could be used in the treatment of solid tumours. METHODS: We evaluated the effect of a novel inhibitor, C1A, on HDAC6 biochemical activity and cell growth. We further examined potential of early noninvasive...
Autores principales: | Kaliszczak, M, Trousil, S, Åberg, O, Perumal, M, Nguyen, Q-D, Aboagye, E O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566806/ https://www.ncbi.nlm.nih.gov/pubmed/23322205 http://dx.doi.org/10.1038/bjc.2012.576 |
Ejemplares similares
-
AKT activation controls cell survival in response to HDAC6 inhibition
por: Kaliszczak, M, et al.
Publicado: (2016) -
Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009) -
Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007) -
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010) -
Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)